Cowen Group Stock News

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the “Neuropsych” panel at Cowen’s 42 nd Annual Healthcare Conference on Monday, March 7, 2022 at 9:10 a.m. ET.

SAN DIEGO, March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a panel discussion and…

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, DPhil, Chief Executive Officer, will participate in a fireside chat at Cowen’s virtual 42nd Annual Health Care Conference on Tuesday, March 8th at 2:10 p.m. EST. A live webc

This Management''s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the consolidated financial statements and related notes of Cowen Inc. included elsewhere in this annual Report on Form 10- K. Actual results may differ materially from those contained in any forward-looking statements. The post COWEN INC. – 10-K – Management''s Discussion and Analysis of Financial Condition and Results of Operations appeared first on InsuranceNewsNet .

LOS ANGELES, March 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. ("Aadi") (NASDAQ: AADI ), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will participate in a panel discussion on Tumor-Agnostic Development and one-on-one investor meetings at Cowen''s 42 nd Annual Health Care Conference, to be held virtually March 7-9, 2022. Panel Details Topic: Tumor-Agnostic Development Date: Tuesday, March 8 th , 2022 Time: 12:50 PM EST Webcast Link: Click Here A replay of the panel discussion will … Full story available on Benzinga.com

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will be participating in the Targeted Oncology Panel at the Cowen & Co 42 nd Annual Health Care Conference, taking place March 7-9, 2022. The Company will also be holding investor meetings at the conference.

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health''s President and Chief Executive Officer, will participate in a panel at the Cowen & Co. 42nd Annual Health Care Conference. Panel Details: Event: Cowen & Co.

Although US stocks closed mixed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate on a panel at Cowen’s 42 nd Annual Health Care Conference which is being held virtually March 7 th through March 9 th , 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control ® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the Company will participate in the Cowen 42 nd Annual Health Care Conference, taking place virtually March 7-9, 2022.

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (NASDAQ: FHTX ), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate on a panel at Cowen''s 42 nd Annual Health Care Conference which is being held virtually March 7 th through March 9 th , 2022. With an initial focus in oncology, Foghorn''s Gene Traffic Control ® Platform … Full story available on Benzinga.com

ESEA, OMVJF, and CROX made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 28, 2022

Cepton (Nsdaq: CPTN) announces its participation in Cowen’s 2nd Annual Mobility Disruption Conference & Berenberg Industrial Technologies Conference

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immuno-oncology panel discussion at the Cowen & Co. 42 nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.

NEW YORK , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) today announced that Brian Hagerty has joined the company’s Equity Capital Markets team as